29 November 2023

CVS Group plc

("CVS" or the "Company")

Result of AGM

CVS, one of the UK's leading providers of integrated veterinary services, announces that at the Company's Annual General Meeting ("AGM") held earlier today, all of the resolutions proposed, as set out in the Notice of AGM, were passed on a poll. Resolutions 1 to 13 were passed as ordinary resolutions and resolutions 14 to 17 were passed as special resolutions.

A summary of proxy votes received for each resolution will shortly be available alongside the Notice of AGM on the Company's website, <u>https://www.cvsukltd.co.uk/investor-centre/agm</u>

Contacts:

CVS Group plc Richard Fairman, CEO	via Camarco
Scott Morrison, Group Company Secretary	
Peel Hunt LLP (Nominated Adviser & Broker) Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose	+44 (0)20 7418 8900
Berenberg (Joint Broker)	+44 (0)20 3207 7800
Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser	
Camarco (Financial PR)	
Geoffrey Pelham-Lane	+44 (0)7733 124 226
Ginny Pulbrook	+44 (0)7961 315 138

About CVS Group plc (www.cvsukitd.co.uk)

CVS Group is an AIM-listed provider of veterinary services in the UK, Australia, the Netherlands and the Republic of Ireland. CVS is focused on providing high quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group has c.500 veterinary practices across its four markets, including nine specialist referral hospitals and 39 dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties), Crematoria (providing pet cremation and clinical waste disposal for CVS and third-party practices), Buying Groups and the Group's online retail business ("Animed Direct").

The Group employs c.9,000 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

•

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <u>ms@lseg.com</u> or visit <u>www.ms.com</u>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END